Drugs / Microgynon 30®
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04131517 | Oct 2019 → May 2020 | — | UCB Biopharma SRL | Terminated | No outcome recorded |
| Phase 1 | NCT02697851 | Jul 2016 → Oct 2017 | HIV infectious disease | St Stephens Aids Trust | Terminated | No outcome recorded |
| Phase 1 | NCT01276262 | Mar → Nov 2011 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01209858 | Mar → Oct 2010 | simple partial epilepsy | Eisai Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Microgynon-30 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01209858 ↗ |
| Route | Oral | “Microgynon-30 single oral dose on Day 1 Period 1 and Day 35 Period 2” NCT01209858 ↗ |